Compensated Awareness Post View
Disclaimer
Ohr Pharmaceutical, Inc. (OHRP) Expanding Presence in Ophthalmology Industry through Development of Groundbreaking Product Pipeline
Ohr Pharmaceutical is an ophthalmology research and development company. Its lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored phase II clinical trials for various back-of-the-eye diseases, including wet age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy. The company’s second product, OHR/AVR118, is designed to treat cancer cachexia, which is commonly known as wasting syndrome. Through these two candidates, Ohr’s product pipeline offers a new ray of hope to patients suffering from these devastating diseases.
Unlike current wet AMD treatment options, which are administered via injection directly into the eye, Ohr’s innovative Squalamine formulation is designed for self-administration, eliminating the need for painful intravitreal injections and providing a significant cost advantage, as compared to the current standards of care. According to a report by the National Eye Institute, wet AMD is a common eye condition and a leading cause of vision loss among people aged 50 and older, affecting over 1.75 million patients in the United States alone. Through the development of Squalamine, Ohr could effectively revolutionize the standard treatment option for this condition, creating a formidable platform to realize significant growth in the ophthalmology market.
In addition to Squalamine, Ohr is addressing a vastly underserved market through the continued development of OHR/AVR118 for the treatment of cancer cachexia. Cancer cachexia is a severe wasting disorder characterized by a significant loss of appetite, weight loss, fatigue, weakness and muscle atrophy. Currently, there is no FDA approved drug for the treatment of this debilitating condition, providing Ohr with another opportunity to realize sustainable increases in shareholder returns.
With a product pipeline including two unique drug candidates in four distinctive indications currently undergoing phase II clinical trials, Ohr is continuing to set the stage for rapid increases in market share in the years to come. For prospective investors, this progress makes Ohr an intriguing option moving forward.
For more information, visit www.ohrpharmaceutical.com
